Jump to content

Coluracetam: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
No edit summary
Line 31: Line 31:
}}
}}


'''Coluracetam''' ([[International Nonproprietary Name|INN]]) (code name '''BCI-540'''; formerly '''MKC-231''') is a [[nootropic]] [[drug|agent]] of the [[racetam]] family.<ref>{{cite journal | last1 = Bessho | first1 = T | last2 = Takashina | first2 = K | last3 = Tabata | first3 = R | last4 = Ohshima | first4 = C | last5 = Chaki | first5 = H | last6 = Yamabe | first6 = H | last7 = Egawa | first7 = M | last8 = Tobe | first8 = A | last9 = Saito | first9 = K | title = Effect of the novel high affinity choline uptake enhancer 2-(2-oxopyrrolidin-1-yl)-N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro2,3-b quinolin-4-yl)acetoamide on deficits of water maze learning in rats | journal = Arzneimittel-Forschung | volume = 46 | issue = 4 | pages = 369–73 | year = 1996 | pmid = 8740080}}</ref> It was initially developed and tested by the [[Mitsubishi Tanabe Pharma Corporation]] for [[Alzheimer's disease]]. After the drug failed to reach endpoints in its clinical trials it was in-licensed by [[BrainCells Inc]] for investigations into [[major depressive disorder]] (MDD), which was preceded by being awarded a "Qualifying Therapeutic Discovery Program Grant" by the state of California.<ref name="CAgrants">[https://www.irs.gov/businesses/small/article/0,,id=228970,00.html Qualifying Therapeutic Discovery Project Grants for the State of California], IRS.gov.</ref> Findings from [[Phases of clinical research#Phase II|phase IIa]] [[clinical trial]]s have suggested that it would be a potential medication for [[comorbidity|comorbid]] MDD with [[generalized anxiety disorder]] (GAD).<ref name="PR-06142010">[http://www.braincellsinc.com/wp-content/uploads/2010/06/BCI-PR-06142010.pdf BrainCells Inc. Announces Results From Exploratory Phase 2a Trial of BCI-540] {{webarchive |url=https://web.archive.org/web/20111121081645/http://www.braincellsinc.com/wp-content/uploads/2010/06/BCI-PR-06142010.pdf |date=November 21, 2011 }}</ref> BrainCells Inc is currently{{when|date=January 2015}} out-licensing the drug for this purpose.<ref name="BCI-540">[Pipeline,BCI-540], BCI-540 (coluracetam).</ref>{{full|date=January 2015}} It may also have potential use in prevention and treatment of [[ischemia|ischemic]] [[retinopathy]] and [[retina]]l and [[optic nerve]] injury.{{medcn|date=January 2015}}
'''Coluracetam''' ([[International Nonproprietary Name|INN]]) (code name '''BCI-540'''; formerly '''MKC-231''') is a [[nootropic]] [[drug|agent]] of the [[racetam]] family.<ref>{{cite journal | last1 = Bessho | first1 = T | last2 = Takashina | first2 = K | last3 = Tabata | first3 = R | last4 = Ohshima | first4 = C | last5 = Chaki | first5 = H | last6 = Yamabe | first6 = H | last7 = Egawa | first7 = M | last8 = Tobe | first8 = A | last9 = Saito | first9 = K | title = Effect of the novel high affinity choline uptake enhancer 2-(2-oxopyrrolidin-1-yl)-N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro2,3-b quinolin-4-yl)acetoamide on deficits of water maze learning in rats | journal = Arzneimittel-Forschung | volume = 46 | issue = 4 | pages = 369–73 | year = 1996 | pmid = 8740080}}</ref> It was initially developed and tested by the [[Mitsubishi Tanabe Pharma Corporation]] for [[Alzheimer's disease]]. After the drug failed to reach endpoints in its clinical trials it was in-licensed by [[BrainCells Inc]] for investigations into [[major depressive disorder]] (MDD), which was preceded by being awarded a "Qualifying Therapeutic Discovery Program Grant" by the state of California.<ref name="CAgrants">[https://www.irs.gov/businesses/small/article/0,,id=228970,00.html Qualifying [[Therapeutic Discovery Project]] Grants for the State of California], IRS.gov.</ref> Findings from [[Phases of clinical research#Phase II|phase IIa]] [[clinical trial]]s have suggested that it would be a potential medication for [[comorbidity|comorbid]] MDD with [[generalized anxiety disorder]] (GAD).<ref name="PR-06142010">[http://www.braincellsinc.com/wp-content/uploads/2010/06/BCI-PR-06142010.pdf BrainCells Inc. Announces Results From Exploratory Phase 2a Trial of BCI-540] {{webarchive |url=https://web.archive.org/web/20111121081645/http://www.braincellsinc.com/wp-content/uploads/2010/06/BCI-PR-06142010.pdf |date=November 21, 2011 }}</ref> BrainCells Inc is currently{{when|date=January 2015}} out-licensing the drug for this purpose.<ref name="BCI-540">[Pipeline,BCI-540], BCI-540 (coluracetam).</ref>{{full|date=January 2015}} It may also have potential use in prevention and treatment of [[ischemia|ischemic]] [[retinopathy]] and [[retina]]l and [[optic nerve]] injury.{{medcn|date=January 2015}}


Coluracetam has been shown to reverse the loss of [[choline acetyltransferase]] production in the [[medial septal nucleus]] of rats exposed to [[PCP (drug)|phencyclidine]] (PCP), and is considered a potential therapeutic drug for [[schizophrenia]].<ref>{{Cite journal
Coluracetam has been shown to reverse the loss of [[choline acetyltransferase]] production in the [[medial septal nucleus]] of rats exposed to [[PCP (drug)|phencyclidine]] (PCP), and is considered a potential therapeutic drug for [[schizophrenia]].<ref>{{Cite journal

Revision as of 20:39, 14 March 2019

Coluracetam
Clinical data
ATC code
  • None
Identifiers
  • N-(2,3-Dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)-2-(2-oxo-1-pyrrolidinyl)acetamide
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H23N3O3
Molar mass341.404 g/mol g·mol−1
3D model (JSmol)
  • Cc1c(oc2c1c(c3c(n2)CCCC3)NC(=O)CN4CCCC4=O)C
  • InChI=1S/C19H23N3O3/c1-11-12(2)25-19-17(11)18(13-6-3-4-7-14(13)20-19)21-15(23)10-22-9-5-8-16(22)24/h3-10H2,1-2H3,(H,20,21,23)
  • Key:PSPGQHXMUKWNDI-UHFFFAOYSA-N

Coluracetam (INN) (code name BCI-540; formerly MKC-231) is a nootropic agent of the racetam family.[1] It was initially developed and tested by the Mitsubishi Tanabe Pharma Corporation for Alzheimer's disease. After the drug failed to reach endpoints in its clinical trials it was in-licensed by BrainCells Inc for investigations into major depressive disorder (MDD), which was preceded by being awarded a "Qualifying Therapeutic Discovery Program Grant" by the state of California.[2] Findings from phase IIa clinical trials have suggested that it would be a potential medication for comorbid MDD with generalized anxiety disorder (GAD).[3] BrainCells Inc is currently[when?] out-licensing the drug for this purpose.[4][full citation needed] It may also have potential use in prevention and treatment of ischemic retinopathy and retinal and optic nerve injury.[medical citation needed]

Coluracetam has been shown to reverse the loss of choline acetyltransferase production in the medial septal nucleus of rats exposed to phencyclidine (PCP), and is considered a potential therapeutic drug for schizophrenia.[5]

Mechanism of action

Coluracetam enhances high-affinity choline uptake (HACU),[6] which is the rate-limiting step of acetylcholine (ACh) synthesis. Studies have shown coluracetam to improve learning impairment on a single oral dose given to rats which have been exposed to cholinergic neurotoxins. Subsequent studies have shown that it may induce long-lasting procognitive effects in cholinergic neurotoxin-treated rats by changing the choline transporter regulation system.[7]

See also

References

  1. ^ Bessho, T; Takashina, K; Tabata, R; Ohshima, C; Chaki, H; Yamabe, H; Egawa, M; Tobe, A; Saito, K (1996). "Effect of the novel high affinity choline uptake enhancer 2-(2-oxopyrrolidin-1-yl)-N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro2,3-b quinolin-4-yl)acetoamide on deficits of water maze learning in rats". Arzneimittel-Forschung. 46 (4): 369–73. PMID 8740080.
  2. ^ Qualifying Therapeutic Discovery Project Grants for the State of California, IRS.gov.
  3. ^ BrainCells Inc. Announces Results From Exploratory Phase 2a Trial of BCI-540 Archived November 21, 2011, at the Wayback Machine
  4. ^ [Pipeline,BCI-540], BCI-540 (coluracetam).
  5. ^ Shirayama, Y; Yamamoto, A; Nishimura, T; Katayama, S; Kawahara, R (2007). "Subsequent exposure to the choline uptake enhancer MKC-231 antagonizes phencyclidine-induced behavioral deficits and reduction in septal cholinergic neurons in rats". European Neuropsychopharmacology. 17 (9): 616–26. doi:10.1016/j.euroneuro.2007.02.011. PMID 17467960.
  6. ^ S. Murai; et al. (1994). "MKC-231, a choline uptake enhancer, ameliorates working memory deficits and decreased hippocampal acetylcholine induced by ethylcholine aziridinium ion in mice". Journal of Neural Transmission. 98 (1): 1–13. doi:10.1007/BF01277590. PMID 7710736.
  7. ^ Bessho, T; Takashina, K; Eguchi, J; Komatsu, T; Saito, K (Jul 2008). "MKC-231, a choline-uptake enhancer: long-lasting cognitive improvement after repeated administration in AF64A-treated rats". Journal of Neural Transmission. 115 (7): 1019–25. doi:10.1007/s00702-008-0053-4. PMID 18461272.

Template:Nootropics

Retrieved from "https://en.wikipedia.org/w/index.php?title=Coluracetam&oldid=887785913"